|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Treatment of gastric cancer显示文摘The authors focused on the current surgical treatment of resectable gastric cancer,and significance of periand post-operative chemo or chemoradiation.Gastric cancer is the 4thmost commonly diagnosed cancer and the second leading cause of cancer death worldwide.Surgery remains the only curative therapy,while perioperative and adjuvant chemotherapy,as well as chemoradiation,can improve outcome of resectable gastric cancer with extended lymph node dissection.More than half of radically resected gastric cancer patients relapse locally or with distant metastases,or receive the diagnosis of gastric cancer when tumor is disseminated;therefore,median survival rarely exceeds12 mo,and 5-years survival is less than 10%.Cisplatin and fluoropyrimidine-based chemotherapy,with addition of trastuzumab in human epidermal growth factor receptor 2 positive patients,is the widely used treatment in stageⅣpatients fit for chemotherapy.Recent evidence supports the use of second-line chemotherapy after progression in patients with good performance | Michele Orditura Gennaro Galizia Vincenzo Sforza Valentina Gambardella Alessio Fabozzi Maria Maddalena Laterza Francesca Andreozzi Jole Ventriglia Beatrice Savastano Andrea Mabilia Eva Lieto Fortunato Ciardiello Ferdinando De Vita | 2014 | World Journal of Gastroenterology2014，20，7： | 116 |
| 2 | Clinical management of advanced gastric cancer: The role of new molecular drugs显示文摘Gastric cancer is the fourth most common malignant neoplasm and the second leading cause of death for cancer in Western countries with more than 20000 new cases yearly diagnosed in the United States.Surgery represents the main approach for this disease but,notwithstanding the advances in surgical techniques,we observed a minimal improvement in terms of overall survival with a significant increasing of relapsing disease rates.Despite the development of new drugs has significantly improved the effectiveness of chemothera-py,the prognosis of patients with unresectable or metastatic gastric adenocarcinoma remains poor.Recently,several molecular target agents have been investigated;in particular,trastuzumab represents the first target molecule showing improvements in overall survival in human epithelial growth factor 2-positive gastric cancer patients.New molecules targeting vascular epithelial growth factor,mammalian target of rapamycin,and anti hepatocyte growth factor-c-Met pathway are also under investigation,with interesting results.Anyway,it seems necessary to select more accurately the population to treat with new agents by the identification of new biomarkers in order to optimize the results.In this paper we review the actual'scenario'of targeted treatments,also focusing on the new agents in development for gastric cancer and gastro-esophageal carcinoma,discussing their efficacy and potential applications in clinical practice. | Ferdinando De Vita Natale Di Martino Alessio Fabozzi Maria Maddalena Laterza Jole Ventriglia Beatrice Savastano Angelica Petrillo Valentina Gambardella Vincenzo Sforza Luigi Marano Annamaria Auricchio Gennaro Galizia Fortunato Ciardiello Michele Orditura | 2014 | World Journal of Gastroenterology2014，20，40： | 12 |
| 3 | Surgical approach to right colon cancer:From open technique to robot.State of art显示文摘This work is a topic highlight on the surgical treatment of the right colon pathologies,focusing on the literature state of art and comparing the open surgery to the different laparoscopic and robotic procedures.Different laparoscopic procedures have been described for the treatment of right colon tumors: Totally laparoscopic right colectomy,laparoscopic assisted right colectomy,laparoscopic facilitated right colectomy,hand-assisted right colectomy,single incision laparoscopic surgery colectomy,robotic right colectomy.Two main characteristics of these techniques are the different type of anastomosis: Intracorporeal(for totally laparoscopic right colectomy,single incision laparoscopic surgery colectomy,laparoscopic assisted right colectomy and robotic technique) or extracorporeal(for laparoscopic assisted right colectomy,laparoscopic facilitated right colectomy,hand-assisted right colectomy and open right colectomy) and the different incision(suprapubic,median or transverse on the right side of abdomen).The different laparoscopic techniques meet the same oncological criteria of radicalism as the open surgery for the right colon.The totally laparoscopic right colectomy with intracorporeal anastomosis and even more the single incision laparoscopic surgery colectomy,remain a technical challenge due to the complexity of procedures(especially for the single incision laparoscopic surgery colectomy) and the particular right colon vascular anatomy but they seem to have some theoretical advantages compared to the other laparoscopic and open procedures.Data reported in literature while confirming the advantages of laparoscopic approach,do not allow to solve controversies about which is the best laparoscopic technique(Intracorporeal vs Extracorporeal Anastomosis) to treat the right colon cancer.However,the laparoscopic techniques with intracorporeal anastomosis for the right colon seem to show some theoretical advantages(functional,technical,oncological and cosmetic advantages) even if all studies conclude that further prospective randomized trials are necessary.Robotic technique may be useful to overcome the problems related to inexperience in laparoscopy in some surgical centers. | Massimiliano Fabozzi Pia Cirillo Francesco Corcione | 2016 | World Journal of Gastrointestinal Surgery2016，8，8： | 8 |
| 4 | Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy显示文摘AIM: To reviewing genetic and epigenetic make-up of metastatic colorectal cancers(m CRCs) addicted to epidermal growth factor receptor(EGFR) signalling.METHODS: The present study summarizes the potential value of prognostic and predictive biomarkers in selecting m CRC patients treated with anti-EGFR therapy. A meta-analysis was performed using a systematic search of Pub Med, Medline and Web of Science to identify eligible papers until March 21 st, 2016 using these following terms: ‘‘colorectal cancer'', 'predictive biomarkers' ', 'anti-EGFR therapy', 'KRAS', 'NRAS'', 'PIK3CA', 'TP53', 'PTEN', ‘‘EGFR', 'MET', 'HER2', 'epiregulin', 'amphiregulin', 'prognostic biomarkers', 'BRAF', 'miR NA' and 'antibody-dependent cell-mediated cytotoxicity(ADCC) activity'. Two investigators independently evaluated and extracted data from each identified studies based on selected criteria of inclusion and exclusion. RESULTS: The introduction of agents targeting EGFR such as cetuximab and panitumumab increased overall survival of mC RCs. Nevertheless, it has firstly became evident that response rates to cetuximab regimens in unselected patient populations were typically lower than 30%. Clinical data confirmed the predictive value of RAS mutations for resistance to cetuximab and panitumumab leading to the license of these monoclonal antibodies exclusively for the management of patients with RAS-wild type colorectal cancers. So far the identification of predictive biomarkers have generated interesting, though preliminary and, at times, conflicting data on the importance of tumour mR NA levels of EGFR ligands, of activating mutations in other genes such as NRAS and PIK3 CA. The prognostic value of selected micro RNAs level and ADCC activity is under investigation, while the prognostic impact of BRAF status remains controversial.CONCLUSION: This review focuses on the personalized treatment of m CRC and discusses the potential of new prognostic and predictive biomarkers in selecting patients treated with anti-EGFR therapy. | Cristiana Lo Nigro Vincenzo Ricci Daniela Vivenza Cristina Granetto Teresa Fabozzi Emanuela Miraglio Marco C Merlano | 2016 | World Journal of Gastroenterology2016，22，30： | 5 |
| 5 | Safety and efficacy of sorafenib in patients with advanced hepatocellularcarcinoma and Child-Pugh A or B cirrhosis显示文摘 | Alessandro Federico Michele Orditura Gaetano Cotticelli Ilario De Sio Marco Romano Antonietta Gravina Marcello Dallio Alessio Fabozzi Fortunato Ciardiello Carmela Loguercio Ferdinando De Vita | 2015 | Oncology Letters2015，，4： | 2 |
| 6 | Predicting Intra- day Price Reversals显示文摘 | Fabozzi F Ma C Chittenden W | 1995 | The Journal of Portfolio Management1995，，21： | 1 |
| 7 | A profit model for spread trading with an application to energy futures 显示文摘 | Kanamura T Raehev S T Fabozzi F J | 2010 | The Journal of Trading2010，5，1： | 1 |
| 8 | Option pricing under stochastic volatility and tempered stable Levy jumps显示文摘 | Zaevski T S Kim Y S Fabozzi F J | 2014 | International Review of Financial Analysis2014，31，1： | 1 |
| 9 | Modernizing the Defined Benefit Pension System显示文摘 | Fabozzi F J Pauling W R | 2005 | The Journal of Portfolio Management2005，31，4： | 1 |
| 10 | Dupilumab: a novel treatment for asthma显示文摘 | Vatrella A Fabozzi I Calabrese C | 2014 | Journal of Asthma and Allergy2014，7，： | 1 |
| 11 | Exploring the components of credit risk in credit default swaps显示文摘 | Frank J. Fabozzi Xiaolin Cheng Ren-Raw Chen | 2006 | Finance Research Letters2006，，1： | 1 |
| 12 | Incorporating the dynamic link between mortgage and treasury markets in pricing and hedging MBS显示文摘 | Bhattacharya A Sekhar A Fabozzi E | 2006 | The Journal of Fixed Income2006，，： | 1 |
| 13 | Robust portfolios: contributions from operations research and finance 显示文摘 | Fabozzi F J Huang D S Zhou G F | 2010 | Annual of Operations Research2010，176，： | 1 |
| 14 | Test of the performance of structure models in bankruptcy prediction显示文摘 | Fabozzi F Chen R Hu S Pan G | 2010 | Journal of Credit Risk2010，6，2： | 1 |
| 15 | Stability test for alphas and betas over bull and bear market conditions显示文摘 | Fabozzi Frank Francis Clark | 1977 | Journal of Finance1977，，9： | 1 |
| 16 | Robust CVaR approach to portfolio selection with uncertain exit time 显示文摘 | HUANG D S ZHU S S FABOZZI F J | 2008 | Journal of Economic Dynamics & Control2008，32，2： | 1 |
| 17 | Estimating risk- neutral density with parametric models in interest rate markets 显示文摘 | Fabozzi F J Tunaru R Albota G | 2009 | Quantitative Finance2009，9，1： | 1 |
| 18 | Dupilumab: a novel treatment for asthma 显示文摘 | Vatrella A Fabozzi I Calabrese C | 2014 | J Asthma Allergy2014，7，： | 1 |
| 19 | CAViaR-based forecast for oil price risk 显示文摘 | Fabozzi F J Fukushima Masao Huang Dashan | 2009 | Energy Economics2009，，31： | 1 |
| 20 | An Autoregressive Conditional Dura-tion Model of Credit-Risk Contagion显示文摘 | Focardi S M Fabozzi F J | 2005 | Journal of Risk Fi-nance2005，6，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员